nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.0868	0.173	CcSEcCtD
Dexmedetomidine—Neuralgia—Topotecan—cervical cancer	0.0326	0.0651	CcSEcCtD
Dexmedetomidine—Pleural effusion—Topotecan—cervical cancer	0.0296	0.059	CcSEcCtD
Dexmedetomidine—Rigors—Topotecan—cervical cancer	0.0278	0.0554	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Topotecan—cervical cancer	0.0249	0.0497	CcSEcCtD
Dexmedetomidine—Respiratory failure—Topotecan—cervical cancer	0.0231	0.046	CcSEcCtD
Dexmedetomidine—ADRA1D—epithelium—cervical cancer	0.0206	0.0612	CbGeAlD
Dexmedetomidine—Sepsis—Topotecan—cervical cancer	0.0197	0.0392	CcSEcCtD
Dexmedetomidine—ADRA1B—renal system—cervical cancer	0.0196	0.058	CbGeAlD
Dexmedetomidine—Cardiac arrest—Topotecan—cervical cancer	0.0156	0.0312	CcSEcCtD
Dexmedetomidine—ADRA1D—female reproductive system—cervical cancer	0.0153	0.0455	CbGeAlD
Dexmedetomidine—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.0148	0.0296	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Topotecan—cervical cancer	0.0145	0.0289	CcSEcCtD
Dexmedetomidine—Pneumonia—Topotecan—cervical cancer	0.0128	0.0254	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Topotecan—cervical cancer	0.0124	0.0248	CcSEcCtD
Dexmedetomidine—SLC6A2—decidua—cervical cancer	0.012	0.0357	CbGeAlD
Dexmedetomidine—Haemoglobin—Topotecan—cervical cancer	0.0114	0.0228	CcSEcCtD
Dexmedetomidine—Haemorrhage—Topotecan—cervical cancer	0.0114	0.0227	CcSEcCtD
Dexmedetomidine—ADRA2C—uterine cervix—cervical cancer	0.0112	0.0332	CbGeAlD
Dexmedetomidine—ADRA2C—decidua—cervical cancer	0.0107	0.0316	CbGeAlD
Dexmedetomidine—ADRA2C—renal system—cervical cancer	0.0105	0.0311	CbGeAlD
Dexmedetomidine—Angiopathy—Topotecan—cervical cancer	0.0103	0.0206	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Topotecan—cervical cancer	0.0103	0.0205	CcSEcCtD
Dexmedetomidine—Chills—Topotecan—cervical cancer	0.0102	0.0204	CcSEcCtD
Dexmedetomidine—ADRA2C—endometrium—cervical cancer	0.0101	0.03	CbGeAlD
Dexmedetomidine—Malnutrition—Topotecan—cervical cancer	0.00991	0.0198	CcSEcCtD
Dexmedetomidine—ADRA2B—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00986	0.0609	CbGpPWpGaD
Dexmedetomidine—ADRA2C—mammalian vulva—cervical cancer	0.00979	0.0291	CbGeAlD
Dexmedetomidine—CYP1A1—epithelium—cervical cancer	0.00966	0.0287	CbGeAlD
Dexmedetomidine—CYP1A1—uterine cervix—cervical cancer	0.00958	0.0284	CbGeAlD
Dexmedetomidine—SLC6A2—female reproductive system—cervical cancer	0.00946	0.0281	CbGeAlD
Dexmedetomidine—ADRA2C—uterus—cervical cancer	0.00933	0.0277	CbGeAlD
Dexmedetomidine—ADRA2C—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00921	0.0569	CbGpPWpGaD
Dexmedetomidine—Anaemia—Topotecan—cervical cancer	0.00916	0.0183	CcSEcCtD
Dexmedetomidine—CYP1A2—renal system—cervical cancer	0.00908	0.027	CbGeAlD
Dexmedetomidine—CYP1A1—renal system—cervical cancer	0.00896	0.0266	CbGeAlD
Dexmedetomidine—ADRA2A—uterine cervix—cervical cancer	0.00893	0.0265	CbGeAlD
Dexmedetomidine—ADRA2A—decidua—cervical cancer	0.00851	0.0253	CbGeAlD
Dexmedetomidine—CYP1A1—mammalian vulva—cervical cancer	0.00838	0.0249	CbGeAlD
Dexmedetomidine—CYP2E1—renal system—cervical cancer	0.00817	0.0243	CbGeAlD
Dexmedetomidine—ADRA2A—endometrium—cervical cancer	0.00808	0.024	CbGeAlD
Dexmedetomidine—Infection—Topotecan—cervical cancer	0.00803	0.016	CcSEcCtD
Dexmedetomidine—CYP1A1—uterus—cervical cancer	0.00798	0.0237	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Topotecan—cervical cancer	0.00792	0.0158	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Topotecan—cervical cancer	0.00782	0.0156	CcSEcCtD
Dexmedetomidine—ADRA2A—mammalian vulva—cervical cancer	0.00781	0.0232	CbGeAlD
Dexmedetomidine—ADRA2C—female gonad—cervical cancer	0.00763	0.0226	CbGeAlD
Dexmedetomidine—ADRA1D—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00762	0.0471	CbGpPWpGaD
Dexmedetomidine—ADRA2C—vagina—cervical cancer	0.00758	0.0225	CbGeAlD
Dexmedetomidine—ADRA2A—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00748	0.0462	CbGpPWpGaD
Dexmedetomidine—ADRA2A—uterus—cervical cancer	0.00744	0.0221	CbGeAlD
Dexmedetomidine—Dyspnoea—Topotecan—cervical cancer	0.00721	0.0144	CcSEcCtD
Dexmedetomidine—CYP1A1—female reproductive system—cervical cancer	0.00718	0.0213	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Topotecan—cervical cancer	0.00698	0.0139	CcSEcCtD
Dexmedetomidine—Pain—Topotecan—cervical cancer	0.00692	0.0138	CcSEcCtD
Dexmedetomidine—Constipation—Topotecan—cervical cancer	0.00692	0.0138	CcSEcCtD
Dexmedetomidine—ADRA2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00688	0.0425	CbGpPWpGaD
Dexmedetomidine—ADRA2A—female reproductive system—cervical cancer	0.00669	0.0199	CbGeAlD
Dexmedetomidine—Feeling abnormal—Topotecan—cervical cancer	0.00666	0.0133	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Topotecan—cervical cancer	0.00661	0.0132	CcSEcCtD
Dexmedetomidine—CYP2E1—female reproductive system—cervical cancer	0.00654	0.0194	CbGeAlD
Dexmedetomidine—CYP1A1—female gonad—cervical cancer	0.00653	0.0194	CbGeAlD
Dexmedetomidine—CYP1A1—vagina—cervical cancer	0.00649	0.0193	CbGeAlD
Dexmedetomidine—CYP2D6—renal system—cervical cancer	0.00647	0.0192	CbGeAlD
Dexmedetomidine—ADRA2C—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00643	0.0397	CbGpPWpGaD
Dexmedetomidine—Abdominal pain—Topotecan—cervical cancer	0.00639	0.0128	CcSEcCtD
Dexmedetomidine—Body temperature increased—Topotecan—cervical cancer	0.00639	0.0128	CcSEcCtD
Dexmedetomidine—ADRA1B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00633	0.0391	CbGpPWpGaD
Dexmedetomidine—ADRA2A—female gonad—cervical cancer	0.00609	0.0181	CbGeAlD
Dexmedetomidine—ADRA2A—vagina—cervical cancer	0.00605	0.018	CbGeAlD
Dexmedetomidine—SLC6A2—lymph node—cervical cancer	0.00554	0.0164	CbGeAlD
Dexmedetomidine—Diarrhoea—Topotecan—cervical cancer	0.00553	0.011	CcSEcCtD
Dexmedetomidine—Dizziness—Topotecan—cervical cancer	0.00535	0.0107	CcSEcCtD
Dexmedetomidine—ADRA2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00522	0.0323	CbGpPWpGaD
Dexmedetomidine—CYP2D6—female reproductive system—cervical cancer	0.00518	0.0154	CbGeAlD
Dexmedetomidine—Vomiting—Topotecan—cervical cancer	0.00514	0.0103	CcSEcCtD
Dexmedetomidine—Rash—Topotecan—cervical cancer	0.0051	0.0102	CcSEcCtD
Dexmedetomidine—Dermatitis—Topotecan—cervical cancer	0.00509	0.0102	CcSEcCtD
Dexmedetomidine—Headache—Topotecan—cervical cancer	0.00507	0.0101	CcSEcCtD
Dexmedetomidine—ADRA2C—lymph node—cervical cancer	0.0049	0.0146	CbGeAlD
Dexmedetomidine—CYP2E1—Folate-Alcohol and Cancer Pathway—MTHFR—cervical cancer	0.00482	0.0298	CbGpPWpGaD
Dexmedetomidine—Nausea—Topotecan—cervical cancer	0.0048	0.00958	CcSEcCtD
Dexmedetomidine—CYP2D6—female gonad—cervical cancer	0.00472	0.014	CbGeAlD
Dexmedetomidine—CYP1A1—lymph node—cervical cancer	0.0042	0.0125	CbGeAlD
Dexmedetomidine—ADRA2A—lymph node—cervical cancer	0.00391	0.0116	CbGeAlD
Dexmedetomidine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00349	0.0216	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Tryptophan metabolism—UBE3A—cervical cancer	0.00336	0.0208	CbGpPWpGaD
Dexmedetomidine—ADRA1D—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.00322	0.0199	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Tryptophan metabolism—UBE3A—cervical cancer	0.00317	0.0196	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.00289	0.0179	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0027	0.0167	CbGpPWpGaD
Dexmedetomidine—ADRA1B—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.00267	0.0165	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00252	0.0156	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00236	0.0146	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.0022	0.0136	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.0021	0.013	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00205	0.0127	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Tryptophan metabolism—UBE3A—cervical cancer	0.00202	0.0125	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00179	0.0111	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Estrogen Receptor Pathway—STAT3—cervical cancer	0.00169	0.0104	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.0015	0.00927	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.0014	0.00867	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—SERPIND1—cervical cancer	0.00139	0.0086	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—GP6—cervical cancer	0.00139	0.0086	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00135	0.00836	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—GP6—cervical cancer	0.0013	0.00803	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—SERPIND1—cervical cancer	0.0013	0.00803	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00126	0.00781	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00124	0.00769	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—GP5—cervical cancer	0.00122	0.00752	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—TAAR6—cervical cancer	0.00114	0.00706	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—GP5—cervical cancer	0.00114	0.00702	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Estrogen Receptor Pathway—STAT3—cervical cancer	0.00108	0.00664	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—GP6—cervical cancer	0.00106	0.00652	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.00106	0.00652	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—TAAR6—cervical cancer	0.00103	0.00637	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00103	0.00635	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—TAAR6—cervical cancer	0.000963	0.00595	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—TAAR6—cervical cancer	0.000948	0.00586	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—GP5—cervical cancer	0.000923	0.0057	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000895	0.00553	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—WNT2—cervical cancer	0.000891	0.00551	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—WNT2—cervical cancer	0.000805	0.00497	CbGpPWpGaD
Dexmedetomidine—ADRA1B—AMPK Signaling—MTOR—cervical cancer	0.000803	0.00497	CbGpPWpGaD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—CASP3—cervical cancer	0.000785	0.00485	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.000782	0.00483	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—WNT2—cervical cancer	0.000752	0.00464	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—WNT2—cervical cancer	0.00074	0.00457	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—WNT5A—cervical cancer	0.000675	0.00417	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—TAAR6—cervical cancer	0.000645	0.00399	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	0.00061	0.00377	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—WNT5A—cervical cancer	0.00061	0.00377	CbGpPWpGaD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—EGFR—cervical cancer	0.000599	0.0037	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—TAAR6—cervical cancer	0.000586	0.00362	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—TAAR6—cervical cancer	0.000582	0.0036	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—WNT5A—cervical cancer	0.00057	0.00352	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—WNT5A—cervical cancer	0.000561	0.00346	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000558	0.00345	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000558	0.00345	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—TAAR6—cervical cancer	0.000544	0.00336	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—TAAR6—cervical cancer	0.000535	0.00331	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—TAAR6—cervical cancer	0.000529	0.00327	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—TAAR6—cervical cancer	0.000494	0.00305	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—TAAR6—cervical cancer	0.000486	0.00301	CbGpPWpGaD
Dexmedetomidine—ADRA1B—AMPK Signaling—TP53—cervical cancer	0.000474	0.00293	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	0.000463	0.00286	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—WNT2—cervical cancer	0.000457	0.00283	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKAP13—cervical cancer	0.000442	0.00273	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	0.000442	0.00273	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—WNT2—cervical cancer	0.000413	0.00255	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKAP13—cervical cancer	0.000402	0.00248	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	0.000401	0.00248	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKAP13—cervical cancer	0.000399	0.00247	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—WNT2—cervical cancer	0.000386	0.00238	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—WNT2—cervical cancer	0.00038	0.00235	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKAP13—cervical cancer	0.000373	0.0023	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKAP13—cervical cancer	0.000367	0.00227	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKAP13—cervical cancer	0.000363	0.00224	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000356	0.0022	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000356	0.0022	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—WNT5A—cervical cancer	0.000347	0.00214	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TAAR6—cervical cancer	0.000346	0.00214	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKAP13—cervical cancer	0.000339	0.00209	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKAP13—cervical cancer	0.000333	0.00206	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	0.000313	0.00194	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—WNT5A—cervical cancer	0.000313	0.00193	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TAAR6—cervical cancer	0.000312	0.00193	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	0.000303	0.00187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—WNT5A—cervical cancer	0.000292	0.00181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TAAR6—cervical cancer	0.000292	0.0018	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—WNT5A—cervical cancer	0.000288	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TAAR6—cervical cancer	0.000287	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	0.000275	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000274	0.00169	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—WNT2—cervical cancer	0.00027	0.00167	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CA9—cervical cancer	0.000257	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—WNT2—cervical cancer	0.000244	0.00151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	0.000237	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKAP13—cervical cancer	0.000237	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	0.000237	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—WNT2—cervical cancer	0.000228	0.00141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000227	0.0014	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—WNT2—cervical cancer	0.000224	0.00139	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKAP13—cervical cancer	0.000214	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CA9—cervical cancer	0.000209	0.00129	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—WNT5A—cervical cancer	0.000205	0.00127	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKAP13—cervical cancer	0.0002	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKAP13—cervical cancer	0.000197	0.00122	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CA9—cervical cancer	0.000192	0.00119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—WNT2—cervical cancer	0.000185	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—WNT5A—cervical cancer	0.000185	0.00114	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CA9—cervical cancer	0.000181	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—WNT5A—cervical cancer	0.000173	0.00107	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—WNT5A—cervical cancer	0.00017	0.00105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	0.000162	0.001	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH2—cervical cancer	0.000144	0.000888	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	0.00014	0.000867	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CA9—cervical cancer	0.000136	0.000842	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH2—cervical cancer	0.00013	0.000802	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH2—cervical cancer	0.000121	0.000749	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH2—cervical cancer	0.000119	0.000737	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HES1—cervical cancer	0.000118	0.000728	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CA9—cervical cancer	0.000115	0.000713	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HES1—cervical cancer	0.000106	0.000657	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—cervical cancer	0.000105	0.000647	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MTHFR—cervical cancer	0.000104	0.000645	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TERT—cervical cancer	0.000103	0.000638	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HES1—cervical cancer	9.94e-05	0.000614	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	9.84e-05	0.000608	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HES1—cervical cancer	9.78e-05	0.000604	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—cervical cancer	9.78e-05	0.000604	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGFR3—cervical cancer	9.47e-05	0.000586	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TERT—cervical cancer	9.32e-05	0.000576	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH1—cervical cancer	8.9e-05	0.00055	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TERT—cervical cancer	8.71e-05	0.000538	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TERT—cervical cancer	8.57e-05	0.00053	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	8.55e-05	0.000529	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MTHFR—cervical cancer	8.48e-05	0.000524	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HES1—cervical cancer	8.07e-05	0.000499	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	8.03e-05	0.000496	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGFR3—cervical cancer	7.99e-05	0.000494	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—cervical cancer	7.94e-05	0.000491	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—cervical cancer	7.93e-05	0.00049	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGFR3—cervical cancer	7.86e-05	0.000486	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—cervical cancer	7.79e-05	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH1—cervical cancer	7.5e-05	0.000464	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH1—cervical cancer	7.38e-05	0.000456	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—cervical cancer	7.34e-05	0.000454	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	7.16e-05	0.000442	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—cervical cancer	7.07e-05	0.000437	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—cervical cancer	6.68e-05	0.000413	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MTOR—cervical cancer	6.67e-05	0.000412	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—cervical cancer	6.58e-05	0.000407	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	6.49e-05	0.000401	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—cervical cancer	6.13e-05	0.000379	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	6.09e-05	0.000377	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—cervical cancer	6.02e-05	0.000372	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—cervical cancer	5.91e-05	0.000365	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—cervical cancer	5.62e-05	0.000347	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—cervical cancer	5.54e-05	0.000342	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—cervical cancer	5.53e-05	0.000342	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—cervical cancer	5.53e-05	0.000342	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	5.43e-05	0.000336	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	5.34e-05	0.00033	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—cervical cancer	5.17e-05	0.00032	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—cervical cancer	5.15e-05	0.000318	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—cervical cancer	5.09e-05	0.000314	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—cervical cancer	4.98e-05	0.000308	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—cervical cancer	4.9e-05	0.000303	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—cervical cancer	4.68e-05	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—cervical cancer	4.68e-05	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—cervical cancer	4.65e-05	0.000287	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—cervical cancer	4.57e-05	0.000282	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—cervical cancer	4.34e-05	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—cervical cancer	4.28e-05	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—cervical cancer	4.23e-05	0.000261	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—cervical cancer	4.2e-05	0.00026	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	4.05e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—cervical cancer	3.95e-05	0.000244	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—cervical cancer	3.93e-05	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—cervical cancer	3.89e-05	0.00024	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—cervical cancer	3.55e-05	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—cervical cancer	3.53e-05	0.000218	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—cervical cancer	3.32e-05	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—cervical cancer	3.26e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—cervical cancer	3.21e-05	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—cervical cancer	2.69e-05	0.000166	CbGpPWpGaD
